Rhythm Pharmaceuticals Stock Forecast
NASDAQ: RYTMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
RYTM analyst consensus
Consensus (18 analysts)
none
Avg. price target
$138.59+56.69%
- Strong buy 5
- Buy 11
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 18 Wall Street analysts covering Rhythm Pharmaceuticals (2026-10-07), 16 rate the stock a buy or strong buy, 2 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $138.59, with a high estimate of $160.00 and a low estimate of $105.00. The average target implies upside of 56.7% from the current price of $88.45.
The spread between the highest and lowest targets is 52.4%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for RYTM.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 5 | 28% |
| Buy | 11 | 61% |
| Hold | 2 | 11% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $105.00 | +18.71% |
| Average target | $138.59 | +56.69% |
| High target | $160.00 | +80.89% |